Finances, Insurance, and Legal Guidance

Chapter Opening: Robert's Story

Robert, a 62-year-old high school teacher, was diagnosed with unfavorable intermediate-risk prostate cancer. He chose radiation therapy with short-term hormone therapy. The treatment itself went smoothly — but the bills did not. Within three months, Robert had received over a dozen separate bills from the hospital, the radiation center, the lab, and the pharmacy. His insurance covered most of the treatment, but the copays, deductibles, and the cost of his hormone therapy added up to over $4,000 out of pocket. He missed 18 days of work during treatment, using up all his sick leave. When he asked about financial help, his cancer team connected him with a financial counselor who helped him apply for a copay assistance program and negotiate a payment plan. "I wish someone had told me about this on day one," Robert says. "The cancer I could handle. The bills almost broke me."

Part 1: Understanding the Cost of Prostate Cancer Care

Cancer treatment is expensive. Even with good insurance, the costs can add up quickly and catch families off guard. Understanding what to expect financially is an important part of preparing for treatment.

What does prostate cancer treatment actually cost?

The total cost of treatment depends on which option you choose, your insurance, and how long treatment lasts. A large study of over 74,000 privately insured men in the United States found the following average total costs over five years after diagnosis¹:

• Conservative management (active surveillance/observation): approximately $48,000 total; about $6,600 out of pocket
• Surgery (radical prostatectomy): approximately $61,000 total; about $7,200 out of pocket
• Radiation therapy: approximately $91,000 total; about $7,500 out of pocket

These are total healthcare system costs — what you personally pay (your out-of-pocket costs) is a fraction of the total, but still significant. Another study of over 30,000 commercially insured men found that in the first six months after diagnosis, out-of-pocket costs averaged about $3,000 for surgery and $3,100 for radiation, compared to about $1,750 for men who did not receive active treatment².

For men with Medicare, a study in JAMA Oncology found that three-year costs ranged from a few thousand dollars for men managed conservatively to over $15,000 for those who received aggressive treatment³.

For advanced prostate cancer, costs are even higher. Oral medications like enzalutamide and abiraterone can cost over $10,000–$20,000 per year out of pocket without assistance⁴. Chemotherapy, immunotherapy, and radiopharmaceuticals (like Lutetium-177 PSMA) add further costs.

Direct vs. indirect costs

Costs fall into two categories:

• Direct costs: Copays, deductibles, coinsurance, medications, imaging, lab tests, procedures, and hospital stays
• Indirect costs: Lost wages from missed work, travel to and from treatment, parking, lodging if treatment is far from home, childcare, and the time your family members spend caring for you instead of working

A systematic review found that 14–58% of cancer patients and their caregivers experience significant loss of income and lost productivity⁵. In the United States, a cancer diagnosis can reduce annual earnings by almost 40% within two years, and total family income can drop by 20%⁶.

What is "financial toxicity"?

Financial toxicity is a medical term — not just a money problem. It describes the distress and hardship that come from the financial burden of cancer treatment⁷. Financial toxicity is now recognized as a real side effect of cancer, just like nausea or fatigue. It can lead to:

• Skipping medications or follow-up appointments to save money
• Increased anxiety, depression, and stress
• Worse treatment outcomes and even shorter survival
• Strained relationships and reduced quality of life

In the CEASAR study of men with localized prostate cancer, 15% reported large or very large financial burden within six months of diagnosis. External beam radiation was associated with the highest financial burden compared to surgery and active surveillance, even after controlling for income and education⁸.

Part 2: Understanding Health Insurance

Health insurance is complicated, and understanding your coverage is one of the most important things you can do after a cancer diagnosis.

Types of insurance in the United States:

• Employer-sponsored insurance: Coverage through your or your spouse's job. This is the most common type for working-age adults.
• Medicare: Federal insurance for adults 65 and older (and some younger adults with disabilities). Includes Part A (hospital), Part B (outpatient/doctor), Part C (Medicare Advantage — private plans), and Part D (prescription drugs).
• Medicaid: State and federal insurance for people with low income. Coverage varies by state.
• Marketplace (ACA) plans: Insurance purchased through Healthcare.gov or state exchanges. Subsidies are available based on income.
• TRICARE / VA: Coverage for military service members, veterans, and their families.

Key insurance terms explained:

• Premium: The monthly amount you pay to have insurance, whether or not you use it
• Deductible: The amount you must pay out of pocket each year before insurance starts covering costs
• Copay: A fixed amount you pay for a specific service (for example, $30 for a doctor visit)
• Coinsurance: The percentage of costs you pay after meeting your deductible (for example, 20% of a procedure)
• Out-of-pocket maximum: The most you will pay in a year. After reaching this amount, insurance covers 100% of covered services.
• Formulary: The list of medications your insurance covers. Drugs not on the formulary may cost much more.
• In-network vs. out-of-network: Providers who have agreements with your insurance (in-network) cost less than those who do not (out-of-network). Some plans do not cover out-of-network care at all.

What to do if you are uninsured or underinsured:

• Apply for Medicaid if you qualify based on income
• Explore ACA marketplace plans — open enrollment occurs annually, but a cancer diagnosis may qualify you for a special enrollment period
• Ask your cancer center about charity care or financial assistance programs — all nonprofit hospitals are required to offer these⁹
• Contact pharmaceutical companies about patient assistance programs for expensive medications

Part 3: The Inflation Reduction Act and Medicare Drug Costs

If you are on Medicare, recent legislation has significantly changed what you pay for prescription drugs.

What changed:

The Inflation Reduction Act (IRA), signed into law in 2022, introduced major changes to Medicare Part D¹⁰:

• 2024: The 5% coinsurance in the catastrophic coverage phase was eliminated. This alone saved patients a median of $7,260 per year on oral cancer medications¹¹.
• 2025 and beyond: A $2,000 annual cap on out-of-pocket prescription drug spending was established. No matter how expensive your medications are, you will not pay more than $2,000 per year for Part D drugs¹².

An estimated 42% of Medicare beneficiaries with cancer were predicted to have annual out-of-pocket drug spending above $2,000 without the cap. With the cap, these patients are expected to save an average of $8,486 per year¹³.

The Medicare Prescription Payment Plan (M3P):

Even with the $2,000 cap, there is a catch: without enrolling in the M3P, the entire $2,000 may be due in January when you fill your first prescription. The M3P allows you to spread your out-of-pocket costs into monthly payments of about $167 per month instead of paying everything upfront¹⁴.

This is especially important for prostate cancer patients on oral medications like enzalutamide or abiraterone. Among Medicare beneficiaries with prostate cancer, 21% of those reaching catastrophic coverage did so in January¹⁵.

Important: Ask your oncology team or pharmacist about enrolling in the M3P before January of each year. Most enrollees are unaware this option exists¹⁶.

A note of caution: While the IRA caps out-of-pocket drug costs, some Part D plans have responded by increasing deductibles and cost-sharing for brand-name drugs, which could partially offset savings for patients who do not reach the $2,000 cap¹⁷.

Part 4: Prior Authorization — What It Is and How to Handle It

Prior authorization (PA) is a process where your insurance company must approve a treatment, test, or medication before they will pay for it. It is one of the most frustrating parts of cancer care for both patients and doctors.

How common is it?

In cancer care, prior authorization is required for¹⁸:

• 71% of imaging studies (CT, MRI, PET scans)
• 48% of chemotherapy treatments
• 47% of surgical procedures
• 34% of radiation therapy

The problem with delays:

• 69% of cancer care is delayed by the PA process
• 51% of delays last two weeks or more
• PA-related anxiety is significantly higher than baseline anxiety in cancer patients¹⁸

Half of patients end up personally involved in the PA process — making phone calls, gathering paperwork, and following up with insurance companies¹⁹.

One patient described the experience: "I was told I had cancer and needed treatment right away. Then I was told I had to wait for my insurance to approve it. It felt like being told your house is on fire but you need a permit to call the fire department"²⁰.

What you can do:

• Ask your cancer team if prior authorization is needed before any test, procedure, or medication
• Keep copies of all paperwork, letters, and phone call records
• Ask your doctor's office to submit PA requests as "urgent" when appropriate
• If PA is delayed, ask your doctor to call the insurance company's medical director directly
• Know that you have the right to appeal any denial

Part 5: Insurance Denials and How to Appeal

Insurance denials happen more often than most people realize. But many denials can be overturned if you appeal.

Why claims get denied:

The most common reasons include²¹:

• "Not medically necessary" — the insurer does not agree the treatment is needed
• Off-label use — the medication is being used for a purpose not specifically listed on its FDA label
• Missing documentation — paperwork was incomplete or not submitted correctly
• Out-of-network provider
• Experimental or investigational treatment

The appeals process:

1. Internal appeal: You (or your doctor) ask the insurance company to review the denial. Include detailed clinical information explaining why the treatment is necessary.
2. External appeal: If the internal appeal is denied, you can request an independent review by a third party not connected to your insurance company.
3. State insurance department: You can file a complaint with your state's department of insurance.

Do appeals work?

Yes. A study in JAMA Internal Medicine found that over 17% of initially denied cancer claims are successfully overturned on appeal. Successful appeals contain high levels of clinical detail — working closely with your doctor on the appeal letter significantly improves your chances²².

Tips for a successful appeal:

• Ask your doctor to write a detailed letter explaining why the treatment is medically necessary, citing clinical guidelines (such as NCCN guidelines) and relevant research
• Include your pathology reports, imaging results, and treatment history
• Keep a timeline of all communications with your insurance company
• Ask your cancer center's patient advocate or social worker for help
• Do not give up after the first denial — many claims are approved on second or third appeal

Part 6: Clinical Trials and Cost

Many patients worry that joining a clinical trial will be more expensive than standard treatment. In most cases, this is not true.

What is covered:

• The investigational drug or treatment is almost always provided free of charge by the trial sponsor²³
• Routine care costs — doctor visits, lab tests, imaging, and hospital stays that you would need regardless of the trial — are typically covered by your insurance²⁴
• The Affordable Care Act requires most private insurers to cover routine care costs for patients in approved clinical trials²⁵
• Medicare covers routine costs for qualifying clinical trials
• The Clinical Treatment Act of 2020 extended this coverage to Medicaid patients²⁶

What may not be covered:

• Extra tests or procedures done purely for research purposes (not for your clinical care)
• Travel, lodging, and meals — though some trials and foundations offer reimbursement
• Time off work

What does the evidence show about costs?

A landmark study in JAMA found that treatment costs for patients in NCI-sponsored clinical trials were only about 6.5% higher than for patients receiving standard care²⁷. A more recent study of advanced lung cancer patients found that clinical trial participants had similar or lower total healthcare costs compared to non-participants²⁸.

Almost half of clinical trial participants report spending at least $1,000 per month out of pocket, primarily from travel expenses and indirect costs²⁹. Financial reimbursement programs are increasingly available — ask your clinical trial team about support.

The bottom line: Do not let cost fears prevent you from considering a clinical trial. Ask your oncology team and the trial coordinator about what will and will not be covered before you enroll.

Part 7: Employment Rights and Workplace Protections

A cancer diagnosis does not mean you have to stop working, and the law provides important protections for your job.

FMLA (Family and Medical Leave Act):

• Provides up to 12 weeks of unpaid, job-protected leave per year
• Applies to employers with 50 or more employees
• You must have worked there for at least 12 months
• Your health insurance continues during leave
• Your job (or an equivalent position) must be available when you return
• Also covers family members who need time off to care for you

ADA (Americans with Disabilities Act):

• Cancer is considered a disability under the ADA
• Requires employers with 15 or more employees to provide reasonable accommodations
• Examples: flexible schedule, work from home, modified duties, extra breaks, reduced hours
• You do not have to disclose your diagnosis to coworkers — only to HR or your supervisor as needed for accommodations

Other protections:

• Many states have additional leave and protection laws beyond federal requirements
• Short-term and long-term disability insurance may provide income replacement
• Social Security Disability Insurance (SSDI) is available for severe cases where you cannot work for 12 months or more

Returning to work:

The NCCN Survivorship Guidelines emphasize that employment is an important source of personal interaction, normalcy, and social support. The psychosocial benefits of work include a sense of purpose, emotional well-being, connection with others, and improved quality of life³⁰. However, some populations face increased difficulties — particularly those with physically demanding jobs, limited scheduling flexibility, or lower educational attainment.

A cancer diagnosis can reduce the probability of being employed by almost 10 percentage points, and hours worked can decline by up to 200 hours in the first year³¹.

Tips:

• Talk to your HR department early about your options
• Ask your cancer center's social worker about workplace rights
• Request accommodations in writing
• Keep documentation of all communications with your employer

Part 8: Legal Navigation and Advocacy

Cancer creates legal challenges that most patients never anticipated. A nationwide study of over 5,800 patients, caregivers, and healthcare professionals found that 48% of cancer patients face two or more legal barriers to care³².

The most common legal issues:

• Health insurance (28%): Navigating claim denials, appeals, coverage gaps
• Finances (21%): Financial assistance, housing instability, medical debt
• Employment (19%): Wrongful termination, working through treatment, taking leave
• Disability insurance (19%): Applying for benefits, navigating denials, transitioning off disability³²

Black and African American patients more often sought help with financial barriers, while White and higher-income patients more frequently needed assistance with health insurance and employment issues³².

Medical-legal partnerships (MLPs):

Approximately 300 medical-legal partnerships exist across the United States, embedding lawyers into healthcare teams to address legal needs at no cost to patients³³. A pilot study at Georgetown University found that cancer patients had an average of two legal issues, most commonly related to Social Security, estate planning, housing, and health insurance. Nearly 75% of patients reported that legal services helped them maintain their treatment regimen³⁴.

Another pilot study in colorectal cancer patients found that even among patients who did not identify their own legal needs, attorneys identified additional issues in 72% of cases, with a median of three legal needs per patient³⁵.

Where to get legal help:

• Triage Cancer (triagecancer.org): Free nationwide legal and financial navigation program
• Cancer Legal Care (cancerlegalcare.org): Free legal services for people affected by cancer
• Patient Advocate Foundation (patientadvocate.org): Case management and insurance appeals
• LegalAid.org: Find free legal aid in your area
• Ask your cancer center's social worker about local medical-legal partnerships

Part 9: The Financial Impact on Caregivers

Cancer does not just affect the patient financially — it ripples outward to the entire family.

The numbers:

• About one-third of cancer caregivers report stopping work, and 30% report increased household debt³⁶
• Cancer caregivers from low-income households are significantly more likely to increase debt and lose income compared to caregivers of people with other conditions³⁶
• In Australia, informal cancer caregivers spend an average of 28.6 hours per week providing care, with an estimated cost of over $60,000 per caregiver per year³⁷
• A scoping review found that unpaid cancer care time is the largest source of caregiver costs, averaging $2,900–$4,800 per month³⁸
• Over 90% of caregivers whose patients experienced health emergencies reported work disruptions³⁹

In a study of caregivers of patients with metastatic colorectal cancer, 57% made a work-related change and 78% experienced a financial impact during 12 months of treatment. Caregivers with children under 18 in the home were nearly six times more likely to make work changes⁴⁰.

What caregivers can do:

• Apply for FMLA leave if eligible (it covers family caregivers too)
• Ask about caregiver support programs at the cancer center
• Contact CancerCare (cancercare.org) for caregiver-specific financial assistance
• Look into respite care services for temporary relief
• Do not neglect your own health — caregiver burnout is real and affects your ability to provide care

Part 10: Financial Assistance Programs and Resources

Help is available — but you often have to ask for it. Do not wait until bills pile up.

Where to start:

• Your cancer center's financial counselor or social worker: This should be your first call. They can help you understand bills, set up payment plans, and apply for assistance programs. Financial navigation programs at cancer centers have been shown to significantly reduce financial distress⁴¹.
• Hospital charity care: All nonprofit hospitals in the United States are required to offer financial assistance programs. Ask about eligibility — income thresholds vary⁹.

Medication assistance:

• Manufacturer patient assistance programs (PAPs): Most pharmaceutical companies offer free or reduced-cost medications for patients who qualify. For prostate cancer, this includes programs for enzalutamide, abiraterone, darolutamide, and others⁴².
• HealthWell Foundation (healthwellfoundation.org): Copay assistance for specific medications
• PAN Foundation (panfoundation.org): Copay assistance
• NeedyMeds (needymeds.org): Database of assistance programs
• RxAssist (rxassist.org): Comprehensive database of patient assistance programs

General financial assistance:

• CancerCare (cancercare.org): Financial assistance grants for treatment-related costs
• Patient Advocate Foundation (patientadvocate.org): Case management, copay relief, insurance appeals
• Family Reach (familyreach.org): Financial assistance for families affected by cancer
• American Cancer Society: Hope Lodge (free lodging near treatment centers), Road to Recovery (free transportation), Health Insurance Assistance Service⁴³

Government programs:

• Medicaid (income-based)
• Social Security Disability Insurance (SSDI)
• Supplemental Security Income (SSI)
• State disability programs
• Veterans' benefits (VA)

Part 11: Practical Financial Strategies

Before treatment begins:

• Ask about costs upfront — request estimates for your treatment plan
• Review your insurance policy carefully, especially your deductible, out-of-pocket maximum, and formulary
• Ask if your cancer center offers a financial counselor or navigator
• If you are on Medicare Part D, enroll in the Medicare Prescription Payment Plan before January

During treatment:

• Request itemized bills and check for errors — billing mistakes are common
• Negotiate payment plans — most hospitals and clinics will work with you
• Track all medical expenses — they may be tax-deductible if they exceed 7.5% of your adjusted gross income
• Understand your Explanation of Benefits (EOB) — this is not a bill, but a summary of what your insurance paid and what you owe
• Consider a Health Savings Account (HSA) or Flexible Spending Account (FSA) if available through your employer

Estate planning basics:

Even if your prognosis is excellent, a cancer diagnosis is a good time to make sure your legal documents are in order:

• Advance directive / living will: Documents your wishes for medical care if you cannot speak for yourself
• Healthcare power of attorney: Names someone to make medical decisions on your behalf
• Financial power of attorney: Names someone to manage your finances if needed
• Will: Ensures your assets are distributed according to your wishes
• Many cancer-focused legal organizations offer these services for free³⁴

Part 12: Disparities in Financial Toxicity

Financial toxicity does not affect everyone equally. Certain groups face disproportionately higher burdens:

• Black and Hispanic patients face higher rates of financial hardship, are more likely to be uninsured or underinsured, and have less access to financial assistance programs³²
• Lower-income families are more likely to experience food insecurity, housing instability, and utility shutoffs during cancer treatment
• Younger patients (under 65) are particularly vulnerable because they are more likely to lose employer-sponsored insurance and have fewer savings
• Rural patients face additional travel costs and may have fewer local resources
• Financial toxicity persists for years after treatment, especially in underserved populations

A study in JAMA Oncology examining debt and bankruptcy after cancer diagnosis found that medical debt in collections increased for multiple cancer types in the years following diagnosis, with effects persisting for years⁴⁴.

Part 13: Talking to Your Doctor About Costs

Many patients feel embarrassed to bring up money with their doctor. But cost conversations are an important part of your care.

Why it matters:

• Your doctor may not know how much your treatment costs you out of pocket
• There may be equally effective but less expensive alternatives
• If cost is causing you to skip medications or appointments, your doctor needs to know — it affects your outcomes

How to bring it up:

• "I'm concerned about the cost of this treatment. Are there alternatives that would work just as well?"
• "I'm having trouble affording my medications. Can you help me find assistance?"
• "Can you connect me with a financial counselor?"

Your cancer center's financial counselors and social workers are trained to help with these conversations. You do not have to figure this out alone.

Part 14: Financial Checklist at Diagnosis

Use this checklist in the first few weeks after your diagnosis:

• □ Review your insurance policy — know your deductible, copays, and out-of-pocket maximum
• □ Ask your cancer center for a financial counselor or social worker
• □ Request cost estimates for your treatment plan
• □ If on Medicare Part D, enroll in the Medicare Prescription Payment Plan
• □ Ask about patient assistance programs for any expensive medications
• □ Understand your FMLA and ADA rights at work
• □ Gather important documents: insurance cards, tax returns, pay stubs
• □ Start tracking all medical expenses and mileage for tax purposes
• □ Ask about clinical trial options — the investigational drug is usually free
• □ Review your estate planning documents (advance directive, power of attorney, will)
• □ Contact Triage Cancer (triagecancer.org) or Patient Advocate Foundation if you need legal or financial navigation help

Part 15: A Note for Readers Outside the United States

The financial landscape of cancer care varies enormously around the world. In countries with universal healthcare systems (such as Canada, the United Kingdom, Australia, and many European nations), direct treatment costs are largely covered by the government. However, patients in these countries may still face:

• Indirect costs such as lost wages, travel, and childcare
• Costs for medications not covered by the national formulary
• Long wait times for certain treatments or imaging
• Out-of-pocket costs for complementary therapies, dental care, or prosthetics

If you live outside the United States, contact your national cancer society or patient advocacy organization for country-specific resources and financial support programs.

Questions to Ask Your Doctor or Financial Counselor

1. What will my treatment cost, and what will my insurance cover?
2. Are there equally effective but less expensive treatment options?
3. Can you connect me with a financial counselor or social worker?
4. Are there patient assistance programs for my medications?
5. Do I qualify for any clinical trials where the drug would be provided free?
6. What are my rights under FMLA and ADA?
7. Is there a medical-legal partnership at this cancer center?
8. If my insurance denies coverage, how do I appeal?
9. Are there programs to help with travel, lodging, or transportation costs?
10. Should I enroll in the Medicare Prescription Payment Plan?

Myth vs. Fact

Myth: "My insurance will cover everything."

Fact: Even with good insurance, out-of-pocket costs for prostate cancer treatment can reach $3,000–$7,500 in the first year alone, and much more for advanced disease requiring oral medications¹ ².

Myth: "Asking about costs means I'll get worse care."

Fact: Discussing costs with your doctor is a normal and important part of treatment planning. It does not change the quality of care you receive — it helps your team find the best plan for your situation.

Myth: "If my insurance denies a treatment, there's nothing I can do."

Fact: Over 17% of denied cancer claims are overturned on appeal. You have the right to appeal every denial²².

Myth: "Clinical trials are more expensive than standard treatment."

Fact: The investigational drug is almost always free, and routine care costs are covered by insurance. Studies show clinical trial participants have similar or lower total costs²⁷ ²⁸.

Myth: "Financial help is only for people with no insurance."

Fact: Many assistance programs are available to insured patients, including copay assistance, manufacturer programs, and nonprofit grants.

Myth: "I'll lose my job if I tell my employer I have cancer."

Fact: The ADA and FMLA provide legal protections. Cancer is considered a disability, and your employer must provide reasonable accommodations.

Key Takeaways

1. Financial toxicity is a real side effect of cancer — it affects quality of life, treatment adherence, and even survival. Ask for financial help early.
2. The Inflation Reduction Act caps Medicare Part D out-of-pocket drug costs at $2,000 per year — enroll in the Medicare Prescription Payment Plan to spread costs monthly.
3. You have the right to appeal insurance denials — over 17% of denied claims are overturned, especially with detailed clinical documentation.
4. Legal protections exist for your job — FMLA provides up to 12 weeks of leave, and the ADA requires reasonable workplace accommodations.
5. Help is available — financial counselors, patient assistance programs, medical-legal partnerships, and nonprofit organizations can reduce your financial burden. Ask your cancer team for referrals.

Support Resources

• Triage Cancer: triagecancer.org — Free legal and financial navigation
• Patient Advocate Foundation: patientadvocate.org — Case management, copay relief, appeals
• CancerCare: cancercare.org — Financial assistance grants, counseling
• American Cancer Society: cancer.org — Hope Lodge, Road to Recovery, insurance assistance
• NeedyMeds: needymeds.org — Database of assistance programs
• HealthWell Foundation: healthwellfoundation.org — Copay assistance
• PAN Foundation: panfoundation.org — Copay assistance
• Family Reach: familyreach.org — Financial assistance for families
• Cancer Legal Care: cancerlegalcare.org — Free legal services
• Medicare Prescription Payment Plan: medicare.gov/m3p — Spread drug costs monthly
• Benefits.gov: benefits.gov — Find government assistance programs
• FMLA information: dol.gov/agencies/whd/fmla
• ADA information: ada.gov

References

1. 1. Housten AJ, et al. Costs of non-metastatic prostate cancer treatment among privately insured men in the United States. PLoS One. 2025;20(5):e0324902.
2. 2. Wallis CJD, et al. Out-of-pocket costs for commercially insured patients with localized prostate cancer. Urol Oncol. 2021;39(12):797–805.
3. 3. Trogdon JG, et al. Total Medicare costs associated with diagnosis and treatment of prostate cancer in elderly men. JAMA Oncol. 2019;5(1):60–66.
4. 4. Joyce DD, Dusetzina SB. Financial toxicity of oral therapies in advanced prostate cancer. Urol Oncol. 2023;41(9):363–368.
5. 5. Alzehr A, et al. The economic impact of cancer diagnosis to individuals and their families: a systematic review. Support Care Cancer. 2022;30(8):6385–6404.
6. 6. Zajacova A, et al. Employment and income losses among cancer survivors: estimates from a national longitudinal survey of American families. Cancer. 2015;121(24):4425–4432.
7. 7. Smith GL, et al. Navigating financial toxicity in patients with cancer: a multidisciplinary management approach. CA Cancer J Clin. 2022;72(5):437–453.
8. 8. Stone BV, et al. Patient-reported financial toxicity associated with contemporary treatment for localized prostate cancer. J Urol. 2021;205(3):761–768.
9. 9. Nonprofit hospital financial assistance programs. ASCO Quality Care Symposium 2025; Abstract 262.
10. 10. Cai CL, et al. Changes in Medicare Part D plan designs after the Inflation Reduction Act. JAMA Intern Med. 2025;2837453.
11. 11. Pockros B, et al. Changes in out-of-pocket spending for common oral cancer medications after the Inflation Reduction Act. JAMA Netw Open. 2024;7(9):e2432456.
12. 12. Doshi JA, et al. Reducing Medicare Part D out-of-pocket costs for specialty oral anticancer drugs under the Inflation Reduction Act. JCO Oncol Pract. 2025;OP2400937.
13. 13. Sepassi A, et al. Estimated true out-of-pocket cost changes of the Inflation Reduction Act on Medicare Part D beneficiaries with cancer. Value Health. 2025;S1098-3015(25)02464-7.
14. 14. Doshi JA, et al. Reducing Medicare Part D out-of-pocket costs for specialty oral anticancer drugs under the Inflation Reduction Act. JCO Oncol Pract. 2025;OP2400937.
15. 15. Sepassi A, et al. Potential impact of the Medicare Prescription Payment Plan for Medicare Part D beneficiaries with a cancer diagnosis. J Clin Oncol. 2026;JCO2501788.
16. 16. Oncology drug abandonment after capping of annual out-of-pocket costs under Medicare Part D in 2024. ASCO Quality Care Symposium 2025; Abstract 97.
17. 17. Cai CL, et al. Changes in Medicare Part D plan designs after the Inflation Reduction Act. JAMA Intern Med. 2025;2837453.
18. 18. Prior authorization delays in cancer care. J Clin Oncol. 2023;41(suppl 16):abstract 6561.
19. 19. Patient involvement in prior authorization. ASCO Quality Care Symposium 2025; Abstract 175.
20. 20. Thom B, et al. Patient perspectives on prior authorization for cancer care. JAMA Netw Open. 2025;8(7):e2523807.
21. 21. Insurance claim denials in cancer care. ASCO Quality Care Symposium 2025; Abstract 204.
22. 22. Rahim A, et al. Overturned health insurance claim denials. JAMA Intern Med. 2026;2847657.
23. 23. Alicea GM, et al. Progress in melanoma treatment: patient's perspectives. Pigment Cell Melanoma Res. 2023;36(6):594–601.
24. 24. Goldman DP, et al. Incremental treatment costs in National Cancer Institute–sponsored clinical trials. JAMA. 2003;289(22):2970–2977.
25. 25. Mackay CB, et al. Insurance denials for cancer clinical trial participation after the Affordable Care Act mandate. Cancer. 2017;123(15):2893–2900.
26. 26. Williams CP, et al. Understanding the clinical treatment act: implications for Medicaid coverage of clinical trial routine care costs. JCO Oncol Pract. 2021;17(7):e921–e928.
27. 27. Goldman DP, et al. Incremental treatment costs in National Cancer Institute–sponsored clinical trials. JAMA. 2003;289(22):2970–2977.
28. 28. Polite BN, et al. Association of clinical trial participation with total healthcare costs in patients with advanced non-small cell lung cancer. Cancer. 2022;128(22):3937–3945.
29. 29. Borno HT, et al. At what cost to clinical trial enrollment? A retrospective study of patient out-of-pocket spending. Oncologist. 2021;26(7):e1218–e1225.
30. 30. NCCN Clinical Practice Guidelines in Oncology: Survivorship. Version 2.2026. National Comprehensive Cancer Network.
31. 31. Yabroff KR, et al. Cancer diagnosis and treatment in working-age adults: implications for employment, health insurance coverage, and financial hardship in the United States. CA Cancer J Clin. 2024;74(4):341–358.
32. 32. Chen KY, et al. Nationwide analysis of legal barriers to cancer care. JAMA Netw Open. 2025;8(7):e2524201.
33. 33. National Center for Medical-Legal Partnership. https://medical-legalpartnership.org.
34. 34. Zuckerman B, et al. Medical-legal partnerships: transforming primary care by addressing the legal needs of vulnerable populations. Health Aff. 2004;23(4):157–166.
35. 35. Fleisher LN, et al. Pilot study of medical-legal partnerships in colorectal cancer patients. J Clin Oncol. 2023;41(suppl 16):abstract 6596.
36. 36. de Moor JS, et al. Opportunities and challenges for addressing financial hardship as an integrated part of cancer care delivery. J Natl Cancer Inst. 2026;djag077.
37. 37. Bates N, et al. The economic cost of informal cancer caregiving in Australia. Support Care Cancer. 2023;31(7):413.
38. 38. Pearce A, et al. Financial toxicity of cancer treatment: a scoping review of the caregiver perspective. Psychooncology. 2023;32(6):850–862.
39. 39. Caregiver work disruptions during cancer treatment. ASCO Quality Care Symposium 2025; Abstract 210.
40. 40. Caregiver financial impact in metastatic colorectal cancer. J Clin Oncol. 2023;41(suppl 16):abstract e18584.
41. 41. Watabayashi K, et al. A pilot study of a comprehensive financial navigation program in patients with cancer and caregivers. J Natl Compr Canc Netw. 2020;18(10):1366–1373.
42. 42. Jeong AY, et al. Characterizing out-of-pocket payments and financial assistance for patients prescribed abiraterone and enzalutamide. JCO Oncol Pract. 2022;18(2):e284–e292.
43. 43. Sharpe K, et al. Practical solutions when facing cost sharing: the American Cancer Society's Health Insurance Assistance Service. Am J Manag Care. 2016;22(4 Suppl):s92–94.
44. 44. Banegas MP, et al. Medical debt and bankruptcy after cancer diagnosis. JAMA Oncol. 2016;2(3):346–352.